AAN 2022 highlighted cutting-edge research in neurology and provided opportunities for networking within the neurology community. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from advances for traumatic brain injury to the future of AI and neurology.
ACTRIMS 2022 highlighted novel scientific discoveries for multiple sclerosis (MS), with a focus on MS biomarkers. Read key takeaways from Peter Ngum, Combinostics Clinical Application Specialist, from better, novel treatments to the potential of enhanced AI-based neuroimaging for improved patient management.
In the third edition of our “Meet the Team” blog series, we talk to Peter Ngum, one of Combinostics’ Clinical Application Specialists, about his academic and industry experience, what he loves about his role, and some fascinating conferences he’s attended recently.
Early detection and differentiation of dementias: with AI, vast amounts of data are an asset, not a burden
Although detection of and differentiation among the various types of dementia remain challenging for clinicians, technological advances such as artificial intelligence (AI) and machine learning (ML) can help.
The theme of RSNA 2021 was “Redefining Radiology,” and, according to our CEO Richard Hausmann, the event delivered. Read Richard’s 5 takeaways, from the potential of AI for radiology to the importance of data for patient care.
Can AI help with patient selection for Aduhelm and other new disease-modifying drugs for Alzheimer’s disease?
Drug development and selection of drugs for patients in clinical practice for Alzheimer’s disease are challenged by many factors, including patient heterogeneity. AI had the potential to help select patients for whom a drug is most suitable — in trials and in practice.